ReviewOncogene2015
Targeting the oncogenic Met receptor by antibodies and gene therapy.
Review in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer.Investigational new drugs · 2023Article
- cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody-Drug Conjugate Targeting c-Met Overexpression Tumors.ACS omega · 2020Article
- MET targeting: time for a rematch.Oncogene · 2020Review
- Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody.Cancers · 2020Article
- Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.Drug design, development and therapy · 2020Article
- Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer.Cancer science · 2019Article
- First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors.Investigational new drugs · 2018Article
- MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner.Journal of hematology & oncology · 2018Article
- Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.International journal of molecular sciences · 2017Article
- MET in human cancer: germline and somatic mutations.Annals of translational medicine · 2017Review
- Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation UsingAdvanced pharmaceutical bulletin · 2017Article
- Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.Experimental & molecular medicine · 2017Review
- MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Oncotarget · 2017Article
- Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies.Scientific reports · 2016Article
- C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.Oncotarget · 2016Article
- Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.Molecular oncology · 2016Article
- Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.Oncotarget · 2016Article
- MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.EMBO molecular medicine · 2016Article
- Molecular targets of luteolin in cancer.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The receptor for hepatocyte growth factor (HGF), a tyrosine kinase encoded by the Met oncogene, has a crucial role in cancer growth, invasion and metastasis. It is a validated therapeutic target for 'personalized' treatment of a number of malignancies. Therapeutic tools prompting selective, robust and highly effective Met inhibition potentially represent a major step in the battle against cancer. Antibodies targeting either Met or its ligand HGF, although challenging, demonstrate to be endowed with promising features. Here we briefly review and discuss the state of the art in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.